Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 5/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL28808001 | 0.97 | FFAR3 (0.41) | FFAR3LCKFYNNQO2CES2 | |
| SCHEMBL5848574 | 0.85 | ALDH1A1 (0.31) | MAPTSMN1; SMN2HPGDALDH1A1KDM4E | |
| Adipic Acid SCHEMBL5395454 | 0.73 | LMNA (0.55) | MAPTTSHRSMN1; SMN2ALDH1A1 | |
| Isopropyl Alcohol SCHEMBL20590526 | 0.71 | ALDH1A1 (0.40) | ALDH1A1TDP1 | |
| Acetic Acid SCHEMBL9623142 | 0.71 | — | — | |
| Acetic Acid SCHEMBL2473166 | 0.69 | SMN1; SMN2 (0.57) | FFAR3LCKFYNNQO2CES2 | |
| SCHEMBL22251585 | 0.69 | ALDH1A1 (0.38) | HSD17B10MAPTTSHRSMN1; SMN2HPGD | |
| Acetic Acid SCHEMBL751998 | 0.67 | SMN1; SMN2 (0.55) | FFAR3LCKFYNNQO2CES2 | |
| Benzene SCHEMBL1761127 | 0.67 | FFAR3 (0.78) | FFAR3LCKFYNCES2CES1 | |
| Benzene SCHEMBL21273372 | 0.67 | FFAR3 (0.78) | FFAR3LCKFYNCES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115343390-B | Method for extracting effective and harmful components in traditional Chinese medicine by matrix solid-phase dispersion | 杭州师范大学 | 2023-08-22 | — | — | CN | claimed |
| US-11174226-B2 | Azetidinimines as carbapenemases inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-11-16 | — | — | US | claimed |
| EP-0283806-B1 | NITRITE AND PHOSPHATE FREE GLYCOL-BASED COOLING MIXTURES | BASF Aktiengesellschaft (DE) | 1990-08-08 | — | — | EP | claimed |
| EP-3347343-B1 | AZETIDINIMINES AS CARBAPENEMASES INHIBITORS | CENTRE NAT RECH SCIENT (FR) | 2023-09-27 | — | — | EP | disclosed |
| CN-115343390-B | Method for extracting effective and harmful components in traditional Chinese medicine by matrix solid-phase dispersion | 杭州师范大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-115343390-A | Method for micro-extracting effective and harmful components in traditional Chinese medicine by matrix solid phase dispersion | 杭州师范大学 | 2022-11-15 | — | — | CN | disclosed |
| CN-110520452-B | (meth) acrylic copolymer, method for producing same, resin composition, and antifouling coating composition | 三菱化学株式会社 | 2022-08-02 | — | — | CN | disclosed |
| CN-114206355-A | Methods and compositions for treating cancer with cancer-targeting adjuvants | 芝加哥大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-110461158-B | Herbicidal mixtures comprising 2- [ (2, 4-dichlorophenyl) methyl ] -4, 4-dimethyl-3-isoxazolidone, topramezone and mefenpyr | 拜耳公司 | 2021-12-10 | — | — | CN | disclosed |
| US-11174226-B2 | Azetidinimines as carbapenemases inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-11-16 | — | — | US | disclosed |
| US-20190055194-A1 | Azetidinimines as Carbapenemases Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2019-02-21 | — | — | US | disclosed |
| CN-109071602-A | Target the cyclic peptide of 4 β of α, 7 integrin | 循环治疗学公司 | 2018-12-21 | — | — | CN | disclosed |
| EP-3347343-A1 | AZETIDINIMINES AS CARBAPENEMASES INHIBITORS | Centre National de la Recherche Scientifique (CNRS) (FR) | 2018-07-18 | — | — | EP | disclosed |
| WO-2017042233-A1 | AZETIDINIMINES AS CARBAPENEMASES INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-03-16 | — | — | WO | disclosed |
| EP-0630888-B1 | IMIDAZOLINE DERIVATIVE, PRODUCTION THEREOF, AND BLOOD PRESSURE RETENTIVE | MAEDA HIROSHI (JP) | 2001-04-04 | — | — | EP | disclosed |
| EP-0606816-B1 | Procedure for preparing salmon calcitonin | LIPOTEC SA (ES) | 1999-08-11 | — | — | EP | disclosed |
| US-5527881-A | SOLID PHASE SYNTHESIS OF FRAGMENTS 1 AND 2 COMPRISING DODECAPEPTIDE AND DECAPEPTIDE, DEPROTECTION TREATMENT OF RESULTING PEPTIDE-RESIN, CLEAVAGE FROM RESIN | LIPOTEC, S.A. (ES) | 1996-06-18 | — | — | US | disclosed |
| US-5464857-A | Smooth muscle relaxants and removal of nitrogen oxides | HIROSHI MAEDA (JP) | 1995-11-07 | — | — | US | disclosed |
| EP-0630888-A1 | IMIDAZOLINE DERIVATIVE, PRODUCTION THEREOF, AND BLOOD PRESSURE RETENTIVE | Maeda, Hiroshi (JP) | 1994-12-28 | — | — | EP | disclosed |
| EP-0606816-A1 | Procedure for preparing salmon calcitonin | LIPOTEC, S.A. (ES) | 1994-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174226-B2 | Azetidinimines as carbapenemases inhibitors | OXA1L, QDPR, PADI1 | FFAR3 4770/4885LCK 4667/4885FYN 4329/4885 |
| US-20190055194-A1 | Azetidinimines as Carbapenemases Inhibitors | OXA1L, QDPR, PADI1 | FFAR3 4770/4885LCK 4667/4885FYN 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.